| everolimus / Generic mfg. |
REVERT, NCT00582738: Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection |
|
|
| Terminated | 2 | 43 | RoW | CsA-TAC (standard Treatment), Everolimus | Novartis Pharmaceuticals | Recurrent Hepatitis C | 01/10 | 01/10 | | |
| Completed | 2 | 33 | Europe | Everolimus, Bevacizumab, RAD001, Avastin | Gerhard Treiber, Crolll Gmbh, Estimate, GmbH, Janssen Diagnostics, LLC | Hepatocellular Carcinoma | 01/11 | 04/12 | | |
|
|
|
| Completed | 2 | 44 | Europe | Everolimus, Afinitor, Octreotide LAR, Sandostatine LAR | Radboud University Medical Center, Novartis | Polycystic Liver Disease | 07/12 | 07/12 | | |
| Completed | 2 | 106 | Europe | everolimus, RAD001, sorafenib tosylate, BAY 43-9006 | Swiss Group for Clinical Cancer Research | Liver Cancer | 06/13 | 03/16 | | |
|
NCT01488487: Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma |
|
|
| Completed | 2 | 24 | US | Everolimus, Afinitor, RAD001, Pasireotide, SOM230, Pasireotide LAR, Pasireotide s.c. | UNC Lineberger Comprehensive Cancer Center, Novartis Pharmaceuticals | Advanced Adult Hepatocellular Carcinoma | 03/15 | 03/15 | | |
NCT01379521: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC |
|
|
| Terminated | 2 | 65 | RoW | everolimus, RAD001, Afinitor®), everolimus placebo | Novartis Pharmaceuticals | Hepatocellular Carcinoma | 06/15 | 06/15 | | |
| Completed | 1/2 | 28 | US | RAD001, Everolimus | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Novartis | Hepatocellular Carcinoma | 01/10 | 11/11 | | |
|
